Craig Dees, PhD is the Chairman and CEO of Provectus Pharmaceuticals. He is also one of the founders. Craig Dees has worked at Photogen Technologies, the Oak Ridge National Laboratory, LipoGen, and TechAmerica. He was a founder, senior scientist and founding director of Photogen before Provectus was formed. Craig's responsibilities have included product design and development in ethical vaccines, cosmetics, human diagnostics, and over-the-counter pharmaceuticals. His development record includes the first live viral vaccine produced by recombinant DNA technologies and the first recombinant antigen human diagnostic assay.
Craig's awards include an R&D 100 for an industrial enzyme, an Inventor's Forum New Product Award for a skincare product, and a First Saber Award for outstanding research in virology. He holds a Ph.D. in molecular virology from University of Wisconsin, Madison, a Master of Science degree in immunology from Auburn University ,and a Bachelor's degree in microbiology from Brigham Young University.
Provectus is a development stage company specializing in oncology and dermatology therapies that are safer, more effective, less invasive and more economical than conventional therapies. Provectus is conducting Phase 2 clinical trials of its proprietary drugs PV-10, as a therapy for metastatic melanoma, and PH-10, as a topical treatment for psoriasis and atopic dermatitis.